Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Iron Deficiency Anemia Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Iron Deficiency Anemia Overview | 8 | 1 |
| Pipeline Products for Iron Deficiency Anemia Comparative Analysis | 9 | 1 |
| Iron Deficiency Anemia Therapeutics under Development by Companies | 10 | 1 |
| Iron Deficiency Anemia Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Iron Deficiency Anemia Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Iron Deficiency Anemia Products under Development by Companies | 15 | 1 |
| Iron Deficiency Anemia Products under Investigation by Universities/Institutes | 16 | 1 |
| Iron Deficiency Anemia Companies Involved in Therapeutics Development | 17 | 6 |
| Galenica Ltd. | 17 | 1 |
| Johnson &Johnson | 18 | 1 |
| Novartis AG | 19 | 1 |
| Panion &Bf Biotech Inc | 20 | 1 |
| Pieris Pharmaceuticals, Inc. | 21 | 1 |
| Rockwell Medical, Inc. | 22 | 1 |
| Iron Deficiency Anemia Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 24 |
| CSJ-137 Drug Profile | 32 | 1 |
| Drug to Repalce Iron for Iron Deficiency Anemia Drug Profile | 33 | 1 |
| ferric carboxymaltose Drug Profile | 34 | 2 |
| ferric citrate Drug Profile | 36 | 8 |
| ferric pyrophosphate citrate Drug Profile | 44 | 7 |
| JNJ-42905343 Drug Profile | 51 | 1 |
| NSC-8679 Drug Profile | 52 | 1 |
| Peptides to Activate Erythroferrone for Iron Deficiency Anemia Drug Profile | 53 | 1 |
| PRS-080 Drug Profile | 54 | 2 |
| Iron Deficiency Anemia Dormant Projects | 56 | 1 |
| Iron Deficiency Anemia Product Development Milestones | 57 | 10 |
| Featured News &Press Releases | 57 | 1 |
| Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston | 57 | 1 |
| Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease | 57 | 2 |
| Mar 21, 2016: China FDA Accepts Rockwell Medical s Triferic Drug Submission for Commercialization in China | 59 | 1 |
| Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia | 60 | 1 |
| Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA | 60 | 1 |
| Dec 01, 2015: Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference | 61 | 1 |
| Nov 30, 2015: Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement | 61 | 1 |
| Oct 28, 2015: Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology Meeting November 2015 | 61 | 1 |
| Oct 06, 2015: Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology Clinical Meeting November 2015 | 62 | 1 |
| Sep 09, 2015: Rockwell Medical Announces the U.S. Commercial Launch of Triferic | 62 | 1 |
| Aug 31, 2015: A meta-analysis on individual-patient data reports that Ferinject treatment of iron deficiency in patients with systolic chronic heart failure is associated with reduced rates of cardiovascular hospitalisations and cardiovascular deaths | 63 | 1 |
| Jul 15, 2015: Rockwell Medical Announces Triferic Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation | 64 | 1 |
| Jul 13, 2015: Rockwell Medical Announces Triferic ESA-Sparing PRIME Study Published in Kidney International | 65 | 1 |
| May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK | 66 | 1 |
| May 05, 2015: Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference | 66 | 1 |
| Appendix | 67 | 2 |
| Methodology | 67 | 1 |
| Coverage | 67 | 1 |
| Secondary Research | 67 | 1 |
| Primary Research | 67 | 1 |
| Expert Panel Validation | 67 | 1 |
| Contact Us | 67 | 1 |
| Disclaimer | 68 | 1 |